Biotest Aktiengesellschaft provided earnings guidance for the year 2019. For financial year 2019, the Board of Management expects sales growth in the mid-single-digit percentage range for continuing operations. The Board of Management expects LBIT from continuing operations to be between EUR 5 million and EBIT from continuing operations of EUR 5 million if partnering can be successfully concluded in 2019.